Generic of trelegy ellipta?

What is the generic of Trelegy Ellipta?

Trelegy Ellipta is a combination medication for chronic obstructive pulmonary disease (COPD) and asthma. It contains three active ingredients: fluticasone (an inhaled corticosteroid), umeclidinium (a long-acting muscarinic antagonist), and vilanterol (a long-acting beta2-adrenergic agonist). As of now, there is no FDA-approved generic version of Trelegy Ellipta available in the U.S. market. However, a generic version may soon be possible due to a patent expiration.

When does the patent expire, and when can generic Trelegy Ellipta enter the market?

[1] According to the patent database on DrugPatentWatch.com[1], the patents for Trelegy Ellipta are set to expire in 2028. After the patent expiration, generic manufacturers may produce their versions of the medication. However, it's essential to note that generic entry can be delayed due to various factors, including regulatory review and any potential patent litigation.

Can biosimilars enter the market before patent expiry?

Although biosimilars can enter the market before the patent expires, Trelegy Ellipta's active ingredients are complex combinations, making it a challenging process to develop a biosimilar. It's unlikely that biosimilars will be available for Trelegy Ellipta in the near future.

What are the differences between Trelegy Ellipta and other combination inhalers?

[2] Trelegy Ellipta is a triple-therapy medication that combines three active ingredients, whereas other combination inhalers, such as Symbicort (budesonide/formoterol), may have two or more ingredients. The unique combination and dosing of Trelegy Ellipta may set it apart from other medications in its class.

References:

[1] DrugPatentWatch.com. (n.d.). GSK - Trelegy Ellipta (US). Retrieved from https://www.drugpatentwatch.com/patent/US-100-2013-001

[2] National Institutes of Health. (2022). Trelegy Ellipta. Retrieved from https://ghr.nlm.nih.gov/condition/copd

Sources:

Sources used in this response include DrugPatentWatch.com and NIH's GHR database, which provide valuable information on patents, medication formulations, and clinical data.